{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T03:57:34Z","timestamp":1764388654511,"version":"3.46.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yang Fan plan of Shanghai Science and Technology Commission Research Project","award":["No.22YF1442700"],"award-info":[{"award-number":["No.22YF1442700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12012-025-10070-y","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:21:56Z","timestamp":1762903316000},"page":"1881-1890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New-Onset Arrhythmias in Advanced Lung Cancer Patients Undergoing Anlotinib Treatment"],"prefix":"10.1007","volume":"25","author":[{"given":"Conghui","family":"Shang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"10299","key":"10070_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021). Lung cancer. Lancet, 398(10299), 535\u2013554. https:\/\/doi.org\/10.1016\/S0140-6736(21)00312-3","journal-title":"Lancet"},{"issue":"135","key":"10070_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1183\/09059180.00011014","volume":"24","author":"J-P Sculier","year":"2015","unstructured":"Sculier, J.-P., Berghmans, T., & Meert, A.-P. (2015). Advances in target therapy in lung cancer. European Respiratory Review, 24(135), 23\u201329. https:\/\/doi.org\/10.1183\/09059180.00011014","journal-title":"European Respiratory Review"},{"issue":"1","key":"10070_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018). Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. Journal of Hematology & Oncology, 11(1), 120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7","journal-title":"Journal of Hematology & Oncology"},{"issue":"11","key":"10070_CR4","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Zhao, Y., Yu, H., Zhao, Y., Chen, W., Luo, Y., Wu, L., Wang, X., & Pirker, R. (2018). Effect of anlotinib as a third-Line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncology, 4(11), 1569\u20131575. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039","journal-title":"JAMA Oncology"},{"issue":"1","key":"10070_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","volume":"12","author":"S Yang","year":"2019","unstructured":"Yang, S., Zhang, Z., & Wang, Q. (2019). Emerging therapies for small cell lung cancer. Journal of Hematology & Oncology, 12(1), 47. https:\/\/doi.org\/10.1186\/s13045-019-0736-3","journal-title":"Journal of Hematology & Oncology"},{"issue":"12","key":"10070_CR6","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1002\/ijc.33161","volume":"147","author":"D Wu","year":"2020","unstructured":"Wu, D., Nie, J., Hu, W., Dai, L., Zhang, J., Chen, X., Ma, X., Tian, G., Han, J., Han, S., Long, J., & Wang, Y. (2020). A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. International Journal of Cancer, 147(12), 3453\u20133460. https:\/\/doi.org\/10.1002\/ijc.33161","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10070_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han, B., Li, K., Zhao, Y., Li, B., Cheng, Y., Zhou, J., Lu, Y., Shi, Y., Wang, Z., Jiang, L., Luo, Y., & Zhang, Y. (2018). Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302). British Journal of Cancer, 118(5), 654\u2013661. https:\/\/doi.org\/10.1038\/bjc.2017.478","journal-title":"British Journal of Cancer"},{"issue":"14","key":"10070_CR8","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1042\/CS20200300","volume":"135","author":"DCH Dorst","year":"2021","unstructured":"Dorst, D. C. H., Doorn, L., Mirabito Colafella, K. M., Manintveld, O. C., Hassing, H. C., & Danser, A. H. J. (2021). Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: Synergistic anti-tumour effects at the cost of increased cardiovascular risk? Clinical Science, 135(14), 1649\u20131668. https:\/\/doi.org\/10.1042\/CS20200300","journal-title":"Clinical Science"},{"issue":"1","key":"10070_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40880-019-0383-7","volume":"39","author":"M Zhou","year":"2019","unstructured":"Zhou, M., Chen, X., Zhang, H., Xia, L., Tong, X., Zou, L., Hao, R., Pan, J., Zhao, X., Chen, D., & Song, Y. (2019). China National medical products administration approval summary: Anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Communications, 39(1), 36. https:\/\/doi.org\/10.1186\/s40880-019-0383-7","journal-title":"Cancer Communications"},{"issue":"3","key":"10070_CR10","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","volume":"144","author":"MG Fradley","year":"2021","unstructured":"Fradley, M. G., Beckie, T. M., Brown, S. A., Cheng, R. K., Dent, S. F., Nohria, A., Patton, K. K., & Singh, J. P. (2021). Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: A scientific statement from the American heart association. Circulation, 144(3), e41\u2013e55. https:\/\/doi.org\/10.1161\/CIR.0000000000000986","journal-title":"Circulation"},{"issue":"15","key":"10070_CR11","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","volume":"142","author":"JE Tisdale","year":"2020","unstructured":"Tisdale, J. E., Chung, M. K., Campbell, K. B., Hammadah, M., Joglar, J. A., Leclerc, J., & Rajagopalan, B. (2020). Drug-Induced arrhythmias: A scientific statement from the American heart association. Circulation, 142(15), e214\u2013e233. https:\/\/doi.org\/10.1161\/CIR.0000000000000905","journal-title":"Circulation"},{"key":"10070_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biom10121673","author":"F Shaik","year":"2020","unstructured":"Shaik, F., Cuthbert, G. A., Homer-Vanniasinkam, S., Muench, S. P., Ponnambalam, S., & Harrison, M. A. (2020). Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy. Biomolecules. https:\/\/doi.org\/10.3390\/biom10121673","journal-title":"Biomolecules"},{"issue":"1","key":"10070_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/CIRCRESAHA.116.303975","volume":"116","author":"LM Ballou","year":"2015","unstructured":"Ballou, L. M., Lin, R. Z., & Cohen, I. S. (2015). Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels. Circulation Research, 116(1), 127\u2013137. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303975","journal-title":"Circulation Research"},{"issue":"5","key":"10070_CR14","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1093\/oncolo\/oyac056","volume":"27","author":"T Isawa","year":"2022","unstructured":"Isawa, T., Toi, Y., Sugawara, S., Taguri, M., & Toyoda, S. (2022). Incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events associated with immune checkpoint inhibitors. The Oncologist, 27(5), e410\u2013e419. https:\/\/doi.org\/10.1093\/oncolo\/oyac056","journal-title":"The Oncologist"},{"issue":"2","key":"10070_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","volume":"1","author":"KR Chitturi","year":"2019","unstructured":"Chitturi, K. R., Xu, J., Araujo-Gutierrez, R., Bhimaraj, A., Guha, A., Hussain, I., Kassi, M., & Bernicker, E. H. (2019). Immune checkpoint Inhibitor-related adverse cardiovascular events in patients with lung cancer. Cardio Oncology, 1(2), 182\u2013192. https:\/\/doi.org\/10.1016\/j.jaccao.2019.11.013","journal-title":"Cardio Oncology"},{"issue":"8","key":"10070_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann, J. (2020). Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nature Reviews. Cardiology, 17(8), 474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1","journal-title":"Nature Reviews. Cardiology"},{"key":"10070_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., & Pauschinger, M. (2016). Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. Journal for Immunotherapy of Cancer, 4, 50. https:\/\/doi.org\/10.1186\/s40425-016-0152-y","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"21","key":"10070_CR18","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier, M., Cautela, J., Malissen, N., Ancedy, Y., Orabona, M., Pinto, J., Monestier, S., & Grob, J. J. (2017). Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation, 136(21), 2085\u20132087. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"},{"issue":"18","key":"10070_CR19","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., & Compton, M. L. (2016). Fulminant myocarditis with combination immune checkpoint Blockade. New England Journal of Medicine, 375(18), 1749\u20131755.","journal-title":"New England Journal of Medicine"},{"key":"10070_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10040540","author":"D Ronen","year":"2022","unstructured":"Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022). Exploring the mechanisms underlying the cardiotoxic effects of immune checkpoint inhibitor therapies. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines10040540","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10070_CR21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu, J. R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., & Padera, R. F. (2019). Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 115(5), 854\u2013868. https:\/\/doi.org\/10.1093\/cvr\/cvz026","journal-title":"Cardiovascular Research"},{"issue":"5","key":"10070_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu, S., Qin, T., Liu, Z., Wang, J., Jia, Y., Feng, Y., Gao, Y., & Li, K. (2020). Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death and Disease, 11(5), 309. https:\/\/doi.org\/10.1038\/s41419-020-2511-3","journal-title":"Cell Death and Disease"},{"issue":"2","key":"10070_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0167-5273(97)00183-6","volume":"62","author":"M Gottwald","year":"1997","unstructured":"Gottwald, M., Gottwald, E., & Dhein, S. (1997). Age-related electrophysiological and histological changes in rabbit hearts: age-related changes in electrophysiology. International Journal of Cardiology, 62(2), 97\u2013106.","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10070_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","volume":"22","author":"VB Pai","year":"2000","unstructured":"Pai, V. B., & Nahata, M. C. (2000). Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Safety, 22(4), 263\u2013302.","journal-title":"Drug Safety"},{"issue":"2","key":"10070_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/030089168607200215","volume":"72","author":"L Canobbio","year":"1986","unstructured":"Canobbio, L., Fassio, T., Gasparini, G., Caruso, G., Barzan, L., Comoretto, R., Brema, F., & Villani, F. (1986). Cardiac arrhythmia: Possible complication from treatment with cisplatin. Tumori Journal, 72(2), 201\u2013204.","journal-title":"Tumori Journal"},{"issue":"2","key":"10070_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1172\/JCI112316","volume":"77","author":"S Bakth","year":"1986","unstructured":"Bakth, S., Arena, J., Lee, W., Torres, R., Haider, B., Patel, B. C., Lyons, M. M., & Regan, T. J. (1986). Arrhythmia susceptibility and myocardial composition in diabetes. Influence of physical conditioning. The Journal of Clinical Investigation, 77(2), 382\u2013395.","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10070_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/01.RES.48.1.39","volume":"48","author":"MS Spach","year":"1981","unstructured":"Spach, M. S., Miller, W. T., Geselowitz, D. B., Barr, R. C., Kootsey, J. M., & Johnson, E. A. (1981). The discontinuous nature of propagation in normal canine cardiac muscle. Evidence for recurrent discontinuities of intracellular resistance that affect the membrane currents. Circulation Research, 48(1), 39\u201354.","journal-title":"Circulation Research"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10070-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-10070-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10070-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T02:44:48Z","timestamp":1764384288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-10070-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10070"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-10070-y","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"type":"print","value":"1530-7905"},{"type":"electronic","value":"1559-0259"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}